Koneksa Completes $16M Series B Financing to Expand Digital Biomarker Platform
Koneksa, a company that develops and implements patient-centric digital biomarkers for drug development, has closed a $16 million Series B financing round. The funds will be used to expand the development of Koneksa’s digital platform for integrating wearables, sensors, and other patient-facing technologies into clinical research. The round was led by Spring Mountain Capital, with new investors McKesson Ventures, Novartis Pharma AG, and MBX Capital. The company’s existing investors also participated in the round. Since its 2015 launch, Koneksa has partnered with pharmaceutical and biotech companies to...